Molecular Partners Stock Forward View - Simple Exponential Smoothing
| MOLN Stock | USD 4.88 -0.02 -0.41% |
Predicting where Molecular Partners' stock will trade is more achievable when sentiment data complements traditional analysis. This module isolates the sentiment-driven component of price to highlight potential mispricings.
At this point in time, RSI for Molecular Partners stands at 55, indicating neutral momentum. Values near 50 generally reflect equilibrium between upward and downward pressure.Momentum
Impartial
Oversold | Overbought |
This section provides headline-driven context for Molecular Partners AG alongside peer activity.
The Simple Exponential Smoothing forecasted value of Molecular Partners AG on the next trading day is expected to be 4.89 with a mean absolute deviation of 0.1 and the sum of the absolute errors of 5.71.Molecular Partners after-hype prediction price | $ 4.88 |
The sentiment panel provides context that can be compared with forecasting models and technical indicators.
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Additional Predictive Modules
Most predictive techniques to examine Molecular price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Molecular using various technical indicators. When you analyze Molecular charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Molecular Partners Simple Exponential Smoothing Price Forecast For the 11th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Molecular Partners AG on the next trading day is expected to be 4.89 with a mean absolute deviation of 0.1 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 5.71 .Please note that although there have been many attempts to predict Molecular Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Molecular Partners' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Molecular Partners Stock Forecast Pattern
| Backtest Molecular Partners | Molecular Partners Price Prediction | Research Analysis |
Molecular Partners Forecasted Value
This next-day forecast for Molecular Partners AG uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Molecular Partners stock data series using in forecasting. Note that when a statistical model is used to represent Molecular Partners stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.0227 |
| Bias | Arithmetic mean of the errors | -0.0138 |
| MAD | Mean absolute deviation | 0.0952 |
| MAPE | Mean absolute percentage error | 0.0213 |
| SAE | Sum of the absolute errors | 5.7132 |
The mean reversion effect in Molecular Partners is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Molecular Partners' price dislocation is essential before acting.
Molecular Partners After-Hype Price Density Analysis
The probability distribution for Molecular Partners' predicted price encodes the full spectrum of outcomes, weighted by their estimated likelihood. Investors should compare this range against their personal risk tolerance before committing to Molecular Partners positions.
Next price density |
| Expected price to next headline |
Molecular Partners Estimiated After-Hype Price Volatility
The news prediction model for Molecular Partners analyzes the correlation between Molecular Partners' historical headline events and same-day or next-day price movements. Molecular Partners' after-hype downside and upside margins for the prediction period are 2.12 and 7.64, respectively. Predictive accuracy varies significantly across different news categories and market regimes for Molecular Partners.
Current Value
The after-hype framework applied to Molecular Partners AG assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Molecular Partners Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Molecular Partners is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Molecular Partners backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Molecular Partners, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 2.76 | 0.00 | 0.00 | 0 Events | 0 Events | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
4.88 | 4.88 | 0.00 |
|
Molecular Partners Hype Timeline
Molecular Partners is now traded for 4.88. The company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Molecular is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at 0.25%. %. The volatility of related hype on Molecular Partners is about 0.0%, with the expected price after the next announcement by competition of 4.88. The company has price-to-book ratio of 1.49. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners recorded a loss per share of 2.09. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be uncertain. Historical Fundamental Analysis of Molecular Partners can be used to cross-verify projections for Molecular Partners. The historical series provides projection context.Molecular Partners Related Hype Analysis
Sector-wide news events often affect Molecular Partners before the fundamental impact on Molecular Partners' own business becomes clear. Peer hype analysis helps investors distinguish between sector-level sentiment shifts and Molecular Partners-specific developments.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APLT | Applied Therapeutics | 0.00 | 0 per month | 0.00 | -0.18 | 10.00 | -11.73 | 45.45 | |
| ELTX | Elicio Therapeutics | 0.00 | 0 per month | 3.13 | 0.19 | 9.51 | -4.34 | 23.99 | |
| CRBP | Corbus Pharmaceuticals Holding | 0.00 | 0 per month | 3.50 | 0.01 | 5.95 | -5.89 | 15.41 | |
| MIST | Milestone Pharmaceuticals | 0.00 | 0 per month | 0.00 | -0.14 | 5.70 | -6.38 | 28.79 | |
| CRDF | Cardiff Oncology | 0.00 | 0 per month | 0.00 | -0.01 | 8.97 | -6.82 | 45.59 | |
| RANI | Rani Therapeutics Holdings | 0.00 | 0 per month | 0.00 | -0.05 | 6.43 | -5.47 | 15.77 | |
| NKTX | Nkarta Inc | 0.00 | 0 per month | 3.39 | 0.15 | 7.84 | -6.34 | 18.98 | |
| PEPG | PepGen | 0.00 | 0 per month | 6.15 | 0.05 | 10.59 | -9.08 | 36.99 | |
| SAVA | Cassava Sciences | 0.00 | 0 per month | 0.00 | -0.06 | 9.05 | -7.69 | 28.15 | |
| ALEC | Alector | 0.00 | 0 per month | 2.80 | 0.26 | 8.68 | -5.08 | 21.36 |
Other Forecasting Options for Molecular Partners
For both new and experienced investors in Molecular, the ability to analyze Molecular Partners' price movement is a fundamental investment skill. Price chart noise in Molecular Stock can create false signals and mislead investment decisions.Molecular Partners Related Equities
The following equities are related to Molecular Partners within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Molecular Partners against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Molecular Partners Market Strength Events
Tracking market strength indicators for Molecular Partners helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Molecular Partners AG for maximum return potential.
Molecular Partners Risk Indicators
Properly assessing Molecular Partners' risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Molecular Partners' allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 2.17 | |||
| Semi Deviation | 2.27 | |||
| Standard Deviation | 2.76 | |||
| Variance | 7.62 | |||
| Downside Variance | 7.07 | |||
| Semi Variance | 5.14 | |||
| Expected Short fall | -2.79 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Molecular Partners
Coverage intensity for Molecular Partners AG matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Molecular Partners Short Properties
Short sentiment tied to Molecular Partners AG matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 34 M | |
| Cash And Short Term Investments | 149.4 M |
More Resources for Molecular Stock Analysis
A comprehensive view of Molecular Partners starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Molecular Partners AG Stock. Key reports that frame Molecular Partners AG Stock are listed below:Historical Fundamental Analysis of Molecular Partners can be used to cross-verify projections for Molecular Partners. The historical series provides projection context.Analysis related to Molecular Partners should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Molecular Partners market price can diverge from book value, the accounting figure shown on Molecular balance sheet. Molecular Partners' market capitalization is 183.26 M. A P/B ratio of 1.49 indicates the market values Molecular Partners above its accounting book value. Enterprise value stands at 43.13 M. Intrinsic value is an analytical estimate of Molecular Partners' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Molecular Partners' value from its trading price, which are computed with different methods. For Molecular Partners, key inputs include a P/E ratio of 1.85, a P/B ratio of 1.49, ROE of -51.42%, and revenue of 4.97 M. By contrast, market price reflects the level where buyers and sellers transact.